{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:11:15Z","timestamp":1791727875462,"version":"4.3.4"},"reference-count":232,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Center Poland","award":["2019\/35\/D\/NZ7\/00174"],"award-info":[{"award-number":["2019\/35\/D\/NZ7\/00174"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Human neurohormone vasopressin (AVP) is synthesized in overlapping regions in the hypothalamus. It is mainly known for its vasoconstricting abilities, and it is responsible for the regulation of plasma osmolality by maintaining fluid homeostasis. Over years, many attempts have been made to modify this hormone and find AVP analogues with different pharmacological profiles that could overcome its limitations. Non-peptide AVP analogues with low molecular weight presented good affinity to AVP receptors. Natural peptide counterparts, found in animals, are successfully applied as therapeutics; for instance, lypressin used in treatment of diabetes insipidus. Synthetic peptide analogues compensate for the shortcomings of AVP. Desmopressin is more resistant to proteolysis and presents mainly antidiuretic effects, while terlipressin is a long-acting AVP analogue and a drug recommended in the treatment of varicose bleeding in patients with liver cirrhosis. Recently published results on diverse applications of AVP analogues in medicinal practice, including potential lypressin, terlipressin and ornipressin in the treatment of SARS-CoV-2, are discussed.<\/jats:p>","DOI":"10.3390\/ijms23063068","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T22:29:43Z","timestamp":1647210583000},"page":"3068","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides"],"prefix":"10.3390","volume":"23","author":[{"given":"Mladena","family":"Glava\u0161","sequence":"first","affiliation":[{"name":"Department of Molecular Biochemistry, Faculty of Chemistry, University of Gda\u0144sk, Wita Stwosza 63, 80-308 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2583-7558","authenticated-orcid":false,"given":"Agata","family":"Gitlin-Domagalska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biochemistry, Faculty of Chemistry, University of Gda\u0144sk, Wita Stwosza 63, 80-308 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-3276","authenticated-orcid":false,"given":"Dawid","family":"D\u0119bowski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biochemistry, Faculty of Chemistry, University of Gda\u0144sk, Wita Stwosza 63, 80-308 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7576-0248","authenticated-orcid":false,"given":"Natalia","family":"Ptaszy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biochemistry, Faculty of Chemistry, University of Gda\u0144sk, Wita Stwosza 63, 80-308 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1665-3180","authenticated-orcid":false,"given":"Anna","family":"\u0141\u0119gowska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biochemistry, Faculty of Chemistry, University of Gda\u0144sk, Wita Stwosza 63, 80-308 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-700X","authenticated-orcid":false,"given":"Krzysztof","family":"Rolka","sequence":"additional","affiliation":[{"name":"Department of Molecular Biochemistry, Faculty of Chemistry, University of Gda\u0144sk, Wita Stwosza 63, 80-308 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3762\/bjoc.10.50","article-title":"Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics","volume":"10","author":"Koopmanschap","year":"2014","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1002\/ejoc.200900599","article-title":"Peptidomimetics\u2014A versatile route to biologically active compounds","volume":"30","author":"Grauer","year":"2009","journal-title":"Eur. J. Org. Chem."},{"key":"ref_3","unstructured":"Vaisman, A., and Lushchak, O. (2020). Geroscience. Encyclopedia of Biomedical Gerontology, Reference Modul in Biomedical Science, Elsevier Inc. Academic Press. [1st ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2174\/0929867323666161213100443","article-title":"Human host defense peptides\u2014Role in maintaining human homeostasis and pathological processes","volume":"24","author":"Dawgul","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1039\/D0CS00102C","article-title":"Peptidomimetic toolbox for drug discovery","volume":"49","author":"Lenci","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, B.K., Ostolaza, H., and Mart\u00edn, C. (2020). Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176275"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cantley, J., and Ashcroft, F.M. (2015). Q&A: Insulin secretion and type 2 diabetes: Why do \u03b2-cells fail?. BMC Biol., 13.","DOI":"10.1186\/s12915-015-0140-6"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fphar.2015.00221","article-title":"\u03b2-Amyloid: The key peptide in the pathogenesis of Alzheimer\u2019s disease","volume":"6","author":"Sun","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"42457","DOI":"10.1039\/D0RA07204D","article-title":"Greening the synthesis of peptide therapeutics: An industrial perspective","volume":"10","author":"Martin","year":"2020","journal-title":"RSC Adv."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, A.C.-L., Harris, J.L., Khanna, K.K., and Hong, J.H. (2019). A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102383"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/0929867024606731","article-title":"Converting a Peptide into a Drug: Strategies to Improve Stability and Bioavailability","volume":"9","author":"Adessi","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.4155\/fmc.12.94","article-title":"Therapeutic peptides","volume":"4","author":"Albericio","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The Current State of Peptide Drug Discovery: Back to the Future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14414","DOI":"10.1002\/anie.201807298","article-title":"Orally Active Peptides: Is There a Magic Bullet?","volume":"57","author":"Reichart","year":"2018","journal-title":"Angew. Chemie-Int. Ed."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10989-021-10177-0","article-title":"A Review on the Metabolism of 25 Peptide Drugs","volume":"27","author":"Chia","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: Barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2174\/0929866521666140807114240","article-title":"Recent advances in protein and Peptide drug delivery: A special emphasis on polymeric nanoparticles","volume":"21","author":"Patel","year":"2014","journal-title":"Protein Pept. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs-from serendipity to rational design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"170555","DOI":"10.1016\/j.peptides.2021.170555","article-title":"Arginine vasopressin: Direct and indirect action on metabolism","volume":"142","author":"Yoshimura","year":"2021","journal-title":"Peptides"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Garrahy, A., and Thompson, C.J. (2018). Vasopressin. Encyclopedia of Endocrine Diseases, Academic Press. [2nd ed.].","DOI":"10.1016\/B978-0-12-801238-3.65216-9"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00134-019-05801-z","article-title":"Vasopressor therapy in critically ill patients with shock","volume":"45","author":"Russell","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12645","article-title":"Vasopressin: Physiology, assessment and osmosentation","volume":"282","author":"Bankir","year":"2017","journal-title":"J. Int. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113784","DOI":"10.1016\/j.expneurol.2021.113784","article-title":"Presynaptic inputs to vasopressin neurons in the hypothalamic supraoptic nucleus and paraventricular nucleus in mice","volume":"343","author":"Wei","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-0040-1710320","article-title":"Vasopressor Therapy in the Intensive Care Unit","volume":"42","author":"Russell","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3934\/molsci.2021003","article-title":"Oxytocin and vasopressin: The social networking buttons of the body","volume":"8","author":"Mitra","year":"2021","journal-title":"AIMS Mol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1113\/jphysiol.1895.sp000565","article-title":"On the physiological action of extracts of the pituitary body and certain other glandular organs","volume":"18","author":"Oliver","year":"1895","journal-title":"J. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1021\/ja01134a528","article-title":"Partial purification and amino acid content of vasopressin from hog posterior. pituitary glands","volume":"74","author":"Popenoe","year":"1952","journal-title":"J. Am. Chem. Soc."},{"key":"ref_30","first-page":"285","article-title":"On phenylalanine-2-lysine-vasopressin","volume":"19","author":"Berde","year":"1961","journal-title":"Helv. Physiol. Pharmacol. Acta"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/hlca.19620450531","article-title":"Syntheses de la Phe2-arginine-vasopressine et de la Phe2-arginine vasotocineet nouvelles synthese de l\u2019argininevasopressine et de l\u2019arginine-vasotocine","volume":"45","author":"Huguenin","year":"1962","journal-title":"Helv. Chim. Acta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF02146034","article-title":"Vasopressin analogues with selective pressor activity","volume":"20","author":"Berde","year":"1964","journal-title":"Experientia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1135\/cccc19664581","article-title":"Amino acids and peptides. Synthesis of ten extended-chain analogues of lysine vasopressin","volume":"31","author":"Kasafire","year":"1966","journal-title":"Coll. Czech. Chem. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/287640a0","article-title":"Phenypressin (Phe2-Arg8-vasopressin), a new neurohypophysial peptide found in marsupials","volume":"287","author":"Chauvet","year":"1980","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wisniewski, K., Galyean, R., Croston, G., Laporte, R., Taki, H., Schteingart, C.D., and Rivi\u00e8re, P.-J.M. (2009). Synthesis and in vitro. pharmacological profile of potent and selective peptidic V1a receptor agonists. Pept. Youth, Springer.","DOI":"10.1007\/978-0-387-73657-0_220"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/jm00122a017","article-title":"Structure-Activity Relationships of Novel Vasopressin Antagonists Containing C-Terminal Diaminoalkanes and (Aminoalkyl)guanidines","volume":"32","author":"Callahan","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/psc.1032","article-title":"Mechanistic studies of amide bond scission during acidolytic deprotection of Pip containing peptide","volume":"14","author":"Rubini","year":"2008","journal-title":"J. Pept. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1039\/D0SC05501H","article-title":"Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin","volume":"12","author":"Dekan","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1021\/ja01115a553","article-title":"The synthesis of an octapeptide amide with the hormonal activity of oxytocin","volume":"75","author":"Wilds","year":"1953","journal-title":"J. Am. Chem. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.neubiorev.2020.12.002","article-title":"The neuroscience of positive emotions and affect: Implications for cultivating happiness and wellbeing","volume":"121","author":"Alexander","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Goh, K.K., Chen, C.-H., and Lane, H.-Y. (2021). Oxytocin in schizophrenia: Pathophysiology and implications for future treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042146"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","article-title":"The oxytocin receptor system: Structure, function, and regulation","volume":"81","author":"Gimpl","year":"2001","journal-title":"Physiol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neubiorev.2020.12.028","article-title":"Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis","volume":"122","author":"Huang","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/295299a0","article-title":"Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor","volume":"295","author":"Land","year":"1982","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.regpep.2010.05.016","article-title":"Arginine-vasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes","volume":"164","author":"Perwitz","year":"2010","journal-title":"Regul. Pept."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biochi.2019.01.008","article-title":"Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival","volume":"158","author":"Mohan","year":"2019","journal-title":"Biochimie"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29462","DOI":"10.1074\/jbc.273.45.29462","article-title":"Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor","volume":"273","author":"Cotte","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.bmc.2005.10.035","article-title":"Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V 1A receptor","volume":"14","author":"Shimada","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.vh.2019.08.015","article-title":"Vasopressin and vasopressin receptors in brain edema","volume":"113","author":"Zeynalov","year":"2020","journal-title":"Vitam. Horm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1016\/j.bmc.2008.09.039","article-title":"Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V2 receptor agonists","volume":"16","author":"Tsukamoto","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/092986607780090810","article-title":"Influence of Conformationally Constrained Amino Acids Replacing Positions 2 and 3 of Arginine Vasopressin (AVP) and Its Analogues on Their Pharmacological Properties","volume":"14","author":"Sobolewski","year":"2017","journal-title":"Protein Pept. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13613-020-0628-2","article-title":"Vasopressin and its analogues in shock states: A review","volume":"10","author":"Demiselle","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1021\/jm1016208","article-title":"Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors","volume":"54","author":"Corbani","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8611","DOI":"10.1021\/bi00099a017","article-title":"Identification of the V1 Vasopressin Receptor by Chemical Cross-Linking and Ligand Affinity Blotting","volume":"30","author":"Estrada","year":"1991","journal-title":"Biochemistry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/psc.600","article-title":"Analogues of arginine vasopressin modified in position 2 and 3 with conformationally constrained dipeptide fragments","volume":"11","author":"Derdowska","year":"2005","journal-title":"J. Pept. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/psc.656","article-title":"The influence of 1-aminocyclopentane-1-carboxylic acid at position 2 or 3 of AVP and its analogues on their pharmacological properties","volume":"11","author":"Kowalczyk","year":"2005","journal-title":"J. Pept. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2165\/00128072-200204120-00003","article-title":"Diabetes insipidus in children: Pathophysiology, diagnosis and management","volume":"4","author":"Cheetham","year":"2002","journal-title":"Pediatr. Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1152\/physrev.00024.2001","article-title":"Aquaporins in the kidney: From molecules to medicine","volume":"1","author":"Nielsen","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrneph.2015.89","article-title":"Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus","volume":"11","author":"Bockenhauer","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1021\/jm8008162","article-title":"New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists","volume":"51","author":"Yea","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.bmc.2009.03.001","article-title":"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists","volume":"17","author":"Tsukamoto","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1113\/jphysiol.2006.119644","article-title":"Cell physiology of cAMP sensor","volume":"577","author":"Holz","year":"2006","journal-title":"Epac. J. Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49026","DOI":"10.1074\/jbc.M408565200","article-title":"Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct","volume":"279","author":"Chou","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/13543780903066764","article-title":"Investigational vasopressin receptor modulators in the pipeline","volume":"18","author":"Favory","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Felmet, K., and Carcillo, J.A. (2006). Neuroendocrine-Immune Mediator Coordination and Disarray in Critical Illness. Pediatric Critical Care, Mosby Inc.","DOI":"10.1016\/B978-032301808-1.50098-5"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/2230-8210.93734","article-title":"Vasopressin receptor antagonists and their role in clinical medicine","volume":"16","author":"Narayen","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1046\/j.1432-1033.2003.03570.x","article-title":"Involvement of the V2 receptor in vasopressin-stimulated translocation of placental leucine aminopeptidase\/oxytocinase in renal cells","volume":"270","author":"Masuda","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0196-9781(02)00138-9","article-title":"Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells","volume":"23","author":"Tahara","year":"2002","journal-title":"Peptides"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"0300060520959494","DOI":"10.1177\/0300060520959494","article-title":"Hemodynamic changes following accidental infiltration of a high dose of vasopressin","volume":"48","author":"Kim","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-12-802175-0.00009-7","article-title":"Vasopressin as a Stress Hormone","volume":"Volume 2","author":"Antoni","year":"2017","journal-title":"Stress: Neuroendocrinology and Neurobiology: Handbook of Stressseries"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.dld.2003.11.017","article-title":"Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices","volume":"36","year":"2004","journal-title":"Dig. Liver Dis."},{"key":"ref_72","unstructured":"(2021, December 11). Vasostrict Informaci\u00f3n Espa\u00f1ola De la Droga. Available online: https:\/\/www.drugs.com\/mtm_esp\/vasostrict.html."},{"key":"ref_73","unstructured":"(2021, December 11). Vasopressin Price of 9 Brands\/Trade Names|Medindia. Available online: https:\/\/www.medindia.net\/drug-price\/vasopressin.htm."},{"key":"ref_74","unstructured":"(2021, December 11). Empressin\u00ae\u2014Amomed. Available online: https:\/\/www.amomed.com\/product\/empressin-3\/?lang=en&cn-reloaded=1."},{"key":"ref_75","unstructured":"(2021, December 11). Reverpleg\u00ae\u2014Amomed. Available online: https:\/\/www.amomed.com\/product\/empressin-3-2\/?lang=fr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jss.2015.02.022","article-title":"Beneficial and side effects of arginine vasopressin and terlipressin for septic shock","volume":"195","author":"Xiao","year":"2015","journal-title":"J. Surg. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1021\/jm070174s","article-title":"The effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: A highly potent V2 agonist","volume":"50","author":"Kowalczyk","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/jm010544r","article-title":"Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V1a receptor","volume":"45","author":"Kakefuda","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.bmc.2006.12.031","article-title":"Azetidinones as vasopressin V1a antagonists","volume":"15","author":"Guillon","year":"2007","journal-title":"Bioorganic Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acs.jmedchem.9b01478","article-title":"Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder","volume":"63","author":"Schnider","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_81","unstructured":"(2021, December 11). Search of: Balovaptan\u2014List Results\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Balovaptan&cntry=&state=&city=&dist=."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1021\/jm000108p","article-title":"Novel design of nonpeptide AVP V2 receptor agonists: Structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template","volume":"43","author":"Kondo","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/jm030287l","article-title":"Synthesis and Structure\u2014Activity Relationships of 5, 6, 7, 8-Tetrahydro-4 H-thieno [3,2-b] azepine Derivatives: Novel Arginine Vasopressin Antagonists","volume":"47","author":"Cho","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_84","unstructured":"Poulani, D. (2002). Vasopressin and Oxytocin, Elsevier Science. [1st ed.]."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1021\/bi00639a018","article-title":"A Raman Spectroscopic Investigation of the Disulfide Conformation in Oxytocin and Lysine Vasopressin","volume":"16","author":"Maxfield","year":"1977","journal-title":"Biochemistry"},{"key":"ref_86","unstructured":"(2021, December 15). Lypressin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lypressin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/bjaceaccp\/mkn021","article-title":"Vasopressin and its role in critical care","volume":"8","author":"Sharman","year":"2008","journal-title":"Contin. Educ. Anaesth. Crit. Care Pain"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jama.1968.03140090187018","article-title":"Ultrasonography for Diagnosis of Orbital Tumors","volume":"203","author":"Dakters","year":"1968","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jcem-24-6-550","article-title":"Treatment of Diabetes Insipidus: Synthetic Lysine Vasopressin Nasal Solution","volume":"24","author":"Dingman","year":"1964","journal-title":"J. Clin. Endocr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0196-9781(85)90390-0","article-title":"The nonmammalian-mammalian transition through neurohypophysial peptides","volume":"6","author":"Acher","year":"1985","journal-title":"Peptides"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1399-3011.1982.tb02617.x","article-title":"Marsupial hypothalamo-neurohypophyseal hormones","volume":"19","author":"Hurpet","year":"1982","journal-title":"Int. J. Pept. Protein Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/EC-18-0046","article-title":"Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH","volume":"7","author":"Jarial","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, H., Ba, Y., Xing, Q., and Cai, R.C. (2020). Differential diagnostic value of bilateral inferior Petrosal sinus sampling (BIPSS) in ACTH-dependent Cushing syndrome: A systematic review and Meta-analysis. BMC Endocr. Disord., 20.","DOI":"10.1186\/s12902-020-00623-3"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/jm00176a020","article-title":"Oxytocin and Lysine-vasopressin with N5,N5-Dialkylglutamine in the 4 Position: Effect of Introducing Sterically Hindered Groups into the Hydrophilic Cluster of Neurohypophyseal Hormones","volume":"23","author":"Stahl","year":"1980","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1021\/jm00265a022","article-title":"Synthesis and Some of the Pharmacological Properties of [4-Leucine]-8-lysine-vasopressin and [1-Deamino,4-leucine]-8-lysine-vasopressin","volume":"16","author":"Dyckes","year":"1973","journal-title":"J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/S0021-9258(18)99528-1","article-title":"The Synthesis and Pharmacological Properties of 4-Decarboxamido-8-lysine-vasopressin, 5-Decarboxamido-8-lysine-vasopressin, and Their 1-Deamino Analogues","volume":"242","author":"Gillessen","year":"1967","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/jm060928n","article-title":"Design and Synthesis of the First Selective Agonists for the Rat Vasopressin V1bReceptor: Based on Modifications of Deamino-[Cys]arginine Vasopressin at Positions 4 and 8","volume":"50","author":"Pena","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0045-2068(75)90048-6","article-title":"Synthesis and some pharmacological properties of [1-beta-mercaptopropionic acid, 2-3,5-dibromo-L-Tyrosine)]-8-Lysine-Vasopressin","volume":"4","author":"Lundell","year":"1975","journal-title":"Bioorg. Chem."},{"key":"ref_99","first-page":"1436","article-title":"Syntheseeines vasopressorisch wirkenden Peptids: 0-Methyl-tyrosin2-Lysin8-Vasopressin (OMTLV)","volume":"96","author":"Siedel","year":"1963","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/jm00202a008","article-title":"Synthesis of O-alkylated lysine-vasopressin, inhibitors of the antidiuretic response to lysine-vasopressin","volume":"21","author":"Larsson","year":"1978","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/jm00242a012","article-title":"Synthesis and some pharmacological properties of [3-.beta.-(2-thienyl)-L-alanine]-8-lysine-vasopressin","volume":"18","author":"Smith","year":"1975","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/jm00198a011","article-title":"[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin synthesis and some pharmacological properties","volume":"22","author":"Banerjee","year":"1979","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/jm00176a021","article-title":"[5-(N4,N4-Dimethylasparagine),8-lysine]vasopressin: The first 5-position neurohypophyseal hormone analog to retain significant antidiuretic potency","volume":"23","author":"Smith","year":"1980","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0196-9781(82)90159-0","article-title":"Central antinociceptive effects of lysine-vasopressin and an analogue","volume":"3","author":"Kordower","year":"1982","journal-title":"Peptides"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/jm00260a017","article-title":"Solid-phase synthesis and pressor potency of [1-deamino-9-ethylenediamine]-lysine-vasopressin","volume":"16","author":"Glass","year":"1973","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0016-6480(83)90008-4","article-title":"Identification of mesotocin, lysine vasopressin, and phenypressin in the eastern gray kangaroo (Macropus giganteus)","volume":"49","author":"Chauvet","year":"1983","journal-title":"Gen. Comp. Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Berde, B., and Boissonnas, R.A. (1968). Basic Pharmacological Properties of Synthetic Analogues and Homologues of the Neurohypophysial Hormones. Neurohypophysial Hormones and Similar Polypeptides, Springer.","DOI":"10.1007\/978-3-642-46127-9"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1021\/jm040813o","article-title":"Highly Potent 1-Aminocyclohexane-1-Carboxylic Acid Substituted V2 Agonists of Arginine Vasopressin","volume":"47","author":"Kowalczyk","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/jm00207a002","article-title":"Design of potent antagonists of the vasopressor response to arginine-vasopressin","volume":"21","author":"Bankowski","year":"1978","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/jm00180a027","article-title":"N-Acetyl-[2-(O-methyl)tyrosine]arginine-vasopressin, an interesting antagonist of the vasopressor response to vasopressin","volume":"23","author":"Jones","year":"1980","journal-title":"J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/j.ejmech.2008.12.010","article-title":"Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists","volume":"44","author":"Kwiatkowska","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_112","unstructured":"Jo\u0161t, K., Lebl, M., and Brtnik, F. (1987). Tables of Analogs in: Handbook of Neurohypophyseal Hormone Analogs, CRC Press. Part 2."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-3011.1997.tb00885.x","article-title":"Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties","volume":"49","author":"Lammek","year":"1997","journal-title":"J. Pept. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/jm00358a018","article-title":"Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7","volume":"26","author":"Grzonka","year":"1983","journal-title":"J. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/jm00156a015","article-title":"Potent vasopressin antagonists lacking the proline residue at position 7","volume":"29","author":"Ali","year":"1986","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/jm00270a002","article-title":"Synthesis and hormonal activities of 8-L-homonorleucine-vasopressin","volume":"16","author":"Fink","year":"1973","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0003-9861(58)90380-1","article-title":"The synthesis of the histidine analog of the vasopressins","volume":"78","author":"Katsoyannis","year":"1958","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/jm00263a009","article-title":"Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin","volume":"16","author":"Manning","year":"1973","journal-title":"J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1517\/13543784.10.5.825","article-title":"Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists","volume":"10","author":"Paranjape","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0079-6123(08)00437-8","article-title":"Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: Research tools and potential therapeutic agents","volume":"170","author":"Manning","year":"2008","journal-title":"Prog. Brain Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1135\/cccc19671250","article-title":"Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-\u03b3-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin","volume":"32","author":"Zaoral","year":"1967","journal-title":"Collect. Czechoslov. Chem. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1135\/cccc19791173","article-title":"Synthesis of (1-\u03b2-mercaptopropionic acid, 8-D-arginine) vasopressin (DDAVP) in solid phase. Simple optimization","volume":"44","author":"Krchnak","year":"1979","journal-title":"Coll. Czech. Chem. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bip.20802","article-title":"Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective","volume":"90","author":"Manning","year":"2008","journal-title":"Biopolymers"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1513\/AnnalsATS.201708-669SD","article-title":"Rationale and Design of an Adaptive Phase 2b\/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock\u2014Adaptive Clinical Trial","volume":"15","author":"Lewis","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.120.000146","article-title":"Protective Mechanism of the Selective Vasopressin V1A Receptor Agonist Selepressin against Endothelial Barrier Dysfunction","volume":"375","author":"Barabutis","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"170318","DOI":"10.1016\/j.peptides.2020.170318","article-title":"Selepressin, a novel selective V1A receptor agonist: Effect on mesenteric flow and gastric mucosa perfusion in the endotoxemic rabbit","volume":"129","author":"Milano","year":"2020","journal-title":"Peptides"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1476-5381.1957.tb00121.x","article-title":"Some Pharmacological Actions of Four Synthetic Analogues Of Oxytocin","volume":"12","author":"Berde","year":"1957","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.4317\/jced.50590","article-title":"Use of anesthetics associated to vasoconstrictors for dentistry in patients with cardiopathies. Review of the literature published in the last decade","volume":"4","author":"Figallo","year":"2012","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.joms.2009.07.080","article-title":"Felypressin, but Not Epinephrine, Reduces Myocardial Oxygen Tension After an Injection of Dental Local Anesthetic Solution at Routine Doses","volume":"68","author":"Inagawa","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/BF03013205","article-title":"Felypressin-induced reduction in coronary blood flow and myocardial tissue oxygen tension during anesthesia in dogs","volume":"46","author":"Agata","year":"1999","journal-title":"Can. J. Anaesth."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S146034","article-title":"In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2","volume":"10","author":"Jamil","year":"2018","journal-title":"J. Exp. Pharmacol."},{"key":"ref_133","first-page":"307","article-title":"Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers","volume":"16","author":"Nilsson","year":"1990","journal-title":"Drugs Under Exp. Clin. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/17474124.1.2.207","article-title":"Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome","volume":"1","author":"Saner","year":"2007","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jgh.14009","article-title":"Terlipressin: Current and emerging indications in chronic liver disease","volume":"33","author":"Papaluca","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/oxfordjournals.humrep.a019413","article-title":"Surgery: Laparoscopic myomectomy of large symptomatic leiomyoma using airlift gasless laparoscopy: A preliminary report","volume":"11","author":"Chang","year":"1996","journal-title":"Hum. Reprod."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2508.1999.00246.x","article-title":"Adhesions after laparoscopic myomectomy: Effect of the technique used","volume":"8","author":"Assaf","year":"2001","journal-title":"Gynaecol. Endosc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.fertnstert.2019.09.016","article-title":"Perioperative nonhormonal pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy: A systematic review and network meta-analysis","volume":"113","author":"Samy","year":"2020","journal-title":"Fertil. Steril."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3892\/mmr.2014.2140","article-title":"Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells","volume":"9","author":"Pastrian","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1007969526447","article-title":"Molecular modeling of the human vasopressin V2 receptor\/agonist complex","volume":"12","author":"Czaplewski","year":"1998","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1021\/jm058038f","article-title":"Analogues of Neurohypophyseal Hormones, Oxytocin and Arginine Vasopressin, Conformationally Restricted in the N-Terminal Part of the Molecule","volume":"49","author":"Kowalczyk","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2826.2012.02303.x","article-title":"Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics","volume":"24","author":"Manning","year":"2012","journal-title":"J. Neuroendocrinol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1210\/endo-94-4-1106","article-title":"Structural Changes in the Arginine Vasopressin Molecule that Enhance Antidiuretic Activity and Specificity1","volume":"94","author":"Sawyer","year":"1974","journal-title":"Endocrinology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1210\/me.2013-1424","article-title":"Altered Agonist Sensitivity of a Mutant V2 Receptor Suggests a Novel Therapeutic Strategy for Nephrogenic Diabetes Insipidus","volume":"28","author":"Balla","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.vh.2019.08.010","article-title":"Development and therapeutic potential of vasopressin synthetic analog [V4Q5]dDAVP as a novel anticancer agent","volume":"113","author":"Garona","year":"2020","journal-title":"Vitam. Horm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.4155\/fmc.11.152","article-title":"\u201cAntiproliferative effect of 1-deamino-8-d-arginine vasopressin analogs on human breast cancer cells","volume":"3","author":"Iannucci","year":"2011","journal-title":"Fut. Med. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10585-016-9799-5","article-title":"Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models","volume":"33","author":"Garona","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3892\/ijo.2015.2952","article-title":"The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models","volume":"46","author":"Garona","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fonc.2017.00011","article-title":"Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells","volume":"7","author":"Pifano","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4143\/crt.2018.040","article-title":"Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer","volume":"51","author":"Garona","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1021\/acs.jmedchem.9b00132","article-title":"Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists","volume":"62","author":"Wisniewski","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40272-020-00401-7","article-title":"Pediatric Pharmacology of Desmopressin in Children with Enuresis: A Comprehensive Review","volume":"22","author":"Gasthuys","year":"2020","journal-title":"Pediatr. Drugs"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.juro.2007.03.015","article-title":"The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children with Nocturnal Enuresis","volume":"178","author":"Robson","year":"2007","journal-title":"J. Urol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ando.2011.09.001","article-title":"Treatment of neurogenic diabetes insipidus","volume":"72","author":"Chanson","year":"2011","journal-title":"Ann. d\u2019Endocrinologie"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00431-013-1992-9","article-title":"Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis","volume":"172","author":"Juul","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.juro.2015.12.089","article-title":"Laparoscopic Versus Abdominal Sacrocolpopexy: A Randomized, Controlled Trial","volume":"196","author":"Costantini","year":"2016","journal-title":"J. Urol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2007.01493.x","article-title":"A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis","volume":"61","author":"Lottmann","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_158","unstructured":"(2021, October 20). Manufactured for: Sanofi-Aventis U.S.; LLC Bridgewater: New York, NY, USA, Patent Nos. 5,498,598; 5,500,413; 5,596,078; 5,674,850; 5,763,407, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/017922s038,018938s027,019955s013lbl.pdf."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2265.1998.00340.x","article-title":"Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects","volume":"48","author":"Rittig","year":"1998","journal-title":"Clin. Endocrinol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/phe.09.20","article-title":"Desmopressin for the treatment of primary nocturnal enuresis","volume":"3","year":"2009","journal-title":"Pediatr. Health"},{"key":"ref_161","first-page":"100082","article-title":"Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration","volume":"3","author":"Kottke","year":"2021","journal-title":"Int. J. Pharm. X"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3109\/10717544.2016.1143056","article-title":"Development andin vitroevaluation of an oral SEDDS for desmopressin","volume":"23","author":"Leonaviciute","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Enna, S., and Bylund, D.B. (2007). Desmopressin. xPharm: The Comprehensive Phamcology Reference, Elsevier Inc.","DOI":"10.1016\/B978-008055232-3.61568-5"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"517","DOI":"10.12968\/hmed.2019.80.9.517","article-title":"Management of nocturia: Overcoming the challenges of nocturnal polyuria","volume":"80","author":"Suman","year":"2019","journal-title":"Br. J. Hosp. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.blre.2014.03.001","article-title":"Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding","volume":"28","author":"Svensson","year":"2014","journal-title":"Blood Rev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3324\/haematol.2017.180059","article-title":"Desmopressin in moderate hemophilia A patients: A treatment worth considering","volume":"103","author":"Loomans","year":"2018","journal-title":"Haematologica"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/rth2.12354","article-title":"Desmopressin responsiveness by age in type 1 von Willebrand disease","volume":"4","author":"Goldberg","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0035-1569070","article-title":"Treatment of von Willebrand Disease","volume":"42","author":"Pasalic","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_173","first-page":"1866","article-title":"Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide","volume":"58","author":"North","year":"1998","journal-title":"Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1469-445X.2000.tb00005.x","article-title":"Gene regulation of vasopressin and vasopressin receptors in cancer","volume":"85","author":"North","year":"2000","journal-title":"Exp. Physiol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00001813-200102000-00006","article-title":"Neuropeptide receptor status in human tumor cell lines","volume":"12","author":"Petit","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0196-9781(99)00070-4","article-title":"MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R","volume":"20","author":"North","year":"1999","journal-title":"Peptides"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-013-2724-6","article-title":"Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model","volume":"142","author":"Ripoll","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0268-9499(97)80255-X","article-title":"139 The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin","volume":"11","author":"Gately","year":"1997","journal-title":"Fibrinolysis Proteolysis"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006291607871","article-title":"Antimetastatic effect of desmopressin in a mouse mammary tumor model","volume":"57","author":"Alonso","year":"1999","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jso.10141","article-title":"Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation","volume":"81","author":"Giron","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tvjl.2007.06.015","article-title":"Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study","volume":"178","author":"Hermo","year":"2007","journal-title":"Vet. J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5326\/JAAHA-MS-5509","article-title":"Effect of Adjuvant Perioperative Desmopressin in Locally Advanced Canine Mammary Carcinoma and its Relation to Histologic Grade","volume":"47","author":"Hermo","year":"2011","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s40064-015-1217-y","article-title":"A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients","volume":"4","author":"Weinberg","year":"2015","journal-title":"SpringerPlus"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/pgmj.2006.052118","article-title":"How do you treat bleeding disorders with desmopressin?","volume":"83","author":"Rajpurkar","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0049-3848(07)70132-9","article-title":"Role of von Willebrand factor in tumor metastasis","volume":"120","author":"Terraube","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s10637-020-00914-5","article-title":"Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: Results of a phase I\/II trial","volume":"38","author":"Iseas","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3892\/etm.2021.9998","article-title":"Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2expressing human osteosarcoma","volume":"21","author":"Sobol","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Hoffman, A., Sasaki, H., Roberto, D., Mayer, M.J., Klotz, L., and Venkateswaran, V. (2016). Effect of Combination therapy of Desmopressin and Docetaxel on prostate cancer cell DU145 proliferation, migration and growth. J. Cancer Biol. Ther., 2.","DOI":"10.18314\/gjct.v2i1.100"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"113","DOI":"10.21873\/anticanres.13086","article-title":"Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model","volume":"39","author":"Bass","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s40265-020-01402-z","article-title":"New Agents in Development for Sepsis: Any Reason for Hope?","volume":"80","author":"Vignon","year":"2020","journal-title":"Drugs"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fphar.2020.00563","article-title":"Clinical Efficiency of Vasopressin or Its Analogs in Comparison with Catecholamines Alone on Patients with Septic Shock: A Systematic Review and Meta-Analysis","volume":"11","author":"Yao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_192","unstructured":"(2021, December 19). Selepressin Evaluation Programme for Sepsis-Induced Shock\u2014Adaptive Clinical Trial\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02508649."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13054-017-1798-7","article-title":"Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients","volume":"21","author":"Russell","year":"2017","journal-title":"Crit. Care"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00000441-196310000-00014","article-title":"CARDIOVASCULAR EFFECTS OF PHENYLALANYL-2-LYSYL-8-VASOPRESSIN (PLV-2)","volume":"246","author":"Ribot","year":"1963","journal-title":"Am. J. Med Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2344\/0003-3006(2006)53[119:CEOF]2.0.CO;2","article-title":"Cardiovascular Effects of Felypressin","volume":"53","author":"Cecanho","year":"2006","journal-title":"Anesth. Prog."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-2044.1994.tb04324.x","article-title":"Single medial injection peribulbar anaesthesia using prilocaine","volume":"49","author":"Brahma","year":"1994","journal-title":"Anaesthesia"},{"key":"ref_197","first-page":"116","article-title":"Vasoconstrictor agents for local anesthesia","volume":"42","author":"Yagiela","year":"1995","journal-title":"Anesth. Prog."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/sj.bdj.4801015a","article-title":"The influence of two different dental local anaesthetic solutions on the haemo-dynamic responses of children undergoing restorative dentistry: A randomised, single-blind, split-mouth study","volume":"190","author":"Meechan","year":"2001","journal-title":"Br. Dent. J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.bdj.4807563","article-title":"The effects of dental local anaesthetics on blood glucose concentration in healthy volunteers and in patients having third molar surgery","volume":"170","author":"Meechan","year":"1991","journal-title":"Br. Dent. J."},{"key":"ref_200","first-page":"138","article-title":"Acute toxicity (LD50 and CD50) of lidocaine and prilocaine in combination with adrenaline and felypressin","volume":"10","author":"Volpato","year":"1999","journal-title":"Indian J. Dent. Res."},{"key":"ref_201","first-page":"108","article-title":"Clinically safe dosage of felypressin for patients with essential hypertension","volume":"43","author":"Sunada","year":"1996","journal-title":"Anesthesia Prog."},{"key":"ref_202","first-page":"5180385","article-title":"Excisional Biopsy of the Pyogenic Granuloma in Very High-Risk Patient","volume":"2018","author":"Nery","year":"2018","journal-title":"Case Rep. Dent."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"215.e1","DOI":"10.1016\/j.joms.2019.09.019","article-title":"Difference in the Effects of Lidocaine with Epinephrine and Prilocaine with Felypressin on the Autonomic Nervous System During Extraction of the Impacted Mandibular Third Molar: A Randomized Controlled Trial","volume":"78","author":"Yamashita","year":"2020","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2344\/anpr-66-02-04","article-title":"Cardiovascular Comparison of 2 Types of Local Anesthesia with Vasoconstrictor in Older Adults: A Crossover Study","volume":"66","author":"Kyosaka","year":"2019","journal-title":"Anesthesia Prog."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"100236","DOI":"10.1016\/j.aohep.2020.07.008","article-title":"An Integrated Review of the Hepatorenal Syndrome","volume":"22","author":"Piano","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17474124.2016.1196132","article-title":"Hepatorenal syndrome in cirrhosis: Diagnostic, pathophysiological, and therapeutic aspects","volume":"10","author":"Busk","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004836-198902000-00014","article-title":"Placebo-Controlled Trial of Terlipressin (Glypressin) in the Management of Acute Variceal Bleeding","volume":"11","author":"Freeman","year":"1989","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.120.3.989","article-title":"Physiology of Vasopressin Relevant to Management of Septic Shock","volume":"120","author":"Holmes","year":"2001","journal-title":"Chest"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/gut.2009.198382","article-title":"Hyponatraemia during terlipressin therapy","volume":"59","author":"Krag","year":"2010","journal-title":"Gut"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/hep.23893","article-title":"Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension","volume":"52","author":"Lens","year":"2010","journal-title":"Hepatology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"F1295","DOI":"10.1152\/ajprenal.90407.2008","article-title":"Effects of terlipressin on the aquaretic system: Evidence of antidiuretic effects","volume":"295","author":"Krag","year":"2008","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apt.12653","article-title":"Review article: Advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction","volume":"39","author":"Leithead","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00004872-199715060-00009","article-title":"Arginine vasopressin inhibits interleukin-1\u03b2-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells","volume":"15","author":"Kusano","year":"1997","journal-title":"J. Hypertens."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"H491","DOI":"10.1152\/ajpheart.1992.263.2.H491","article-title":"Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery","volume":"263","author":"Wakatsuki","year":"1992","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0168-8278(99)80112-3","article-title":"Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs","volume":"30","author":"Hansen","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1530\/acta.0.0810474","article-title":"In vivo activation of synthetic hormonogens of lysine vasopressin: N\u03b1-glycyl-glycyl-glycyl-[8-lysine]vasopressin in the cat","volume":"81","author":"Chard","year":"1976","journal-title":"Eur. J. Endocrinol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bpa.2008.02.002","article-title":"Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage","volume":"22","author":"Meyer","year":"2008","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gut.38.1.129","article-title":"Assessment of variceal pressureby continous non-invasive endoscopic registration: A placebo controlled evaluation of the effect of terlipressin and octerotide","volume":"38","author":"Nevens","year":"1996","journal-title":"Gut"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-0676.2000.020001051.x","article-title":"Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients","volume":"20","author":"Hansen","year":"2000","journal-title":"Liver Int."},{"key":"ref_220","first-page":"CD002147","article-title":"Terlipressin for acute esophageal variceal hemorrhage","volume":"2003","author":"Ioannou","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bpg.2007.11.001","article-title":"Acute variceal bleeding: Pharmacological treatment and primary\/secondary prophylaxis","volume":"22","author":"Iannuzzi","year":"2008","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5114\/pg.2010.14138","article-title":"Management of variceal haemorrhage","volume":"3","author":"Dabrowski","year":"2010","journal-title":"Gastroenterol. Rev."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/a-0846-3071","article-title":"Vasoactive agents for the management of variceal bleeding: A mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"69","author":"Sridharan","year":"2019","journal-title":"Drug Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14740338.2020.1734558","article-title":"Development of hyponatremia after terlipressin in cirrhotic patients with acute gastrointestinal bleeding: A retrospective multicenter observational study","volume":"19","author":"Xu","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/jcpt.13031","article-title":"Severe hyponatraemia with neurological manifestations in patients treated with terlipressin: Two case reports","volume":"44","author":"Meng","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jcpt.13057","article-title":"Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin","volume":"45","author":"Pan","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/app.31876","article-title":"Preparation and characterization of PEGylated terlipressin","volume":"116","author":"Wang","year":"2010","journal-title":"J. Appl. Polym. Sci."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"596654","DOI":"10.3389\/fendo.2021.596654","article-title":"Case Report: SARS-CoV-2 Infection in a Child with Suprasellar Tumor and Hypothalamic-Pituitary Failure","volume":"12","author":"Gaudino","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"112193","DOI":"10.1016\/j.biopha.2021.112193","article-title":"Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective","volume":"143","author":"Qusti","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_230","first-page":"1","article-title":"Diabetes Insipidus and Concomitant Myocarditis: A Late Sequelae of COVID-19 Infection","volume":"9","author":"Sheikh","year":"2021","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1021\/acs.jproteome.0c00383","article-title":"In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins","volume":"19","author":"Maffucci","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"e04502","DOI":"10.1016\/j.heliyon.2020.e04502","article-title":"SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)\u2014A drug repurposing study","volume":"6","author":"Ahmad","year":"2020","journal-title":"Heliyon"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3068\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:29Z","timestamp":1760135729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":232,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063068"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063068","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]}}}